
Doximity, McKesson, and ResMed are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare, such as pharmaceuticals, biotechnology, medical devices, healthcare services, or health insurance. Investors may consider these stocks based on factors including drug development, regulatory approvals, demand for medical services, and broader healthcare trends. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Doximity (DOCS)
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
McKesson (MCK)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Read Our Latest Research Report on MCK
ResMed (RMD)
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Read Our Latest Research Report on RMD
See Also
- MarketBeat’s Top Five Stocks to Own in August 2026
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
- Why the Landlord of the AI Boom Could Outlast the Chipmakers
- AST SpaceMobile’s Latest BlueBird Launch Raises the Stakes Ahead of Q2 Earnings
